Nanjing Well Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 0.12%

Nanjing Well Pharmaceutical Co Ltd (603351) has an Asset Resilience Ratio of 0.12% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Nanjing Well Pharmaceutical Co Ltd total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥3.00 Million

≈ $438.99K USD Cash + Short-term Investments

Total Assets

CN¥2.59 Billion

≈ $378.33 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2023)

This chart shows how Nanjing Well Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See Nanjing Well Pharmaceutical Co Ltd (603351) shareholders funds for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Nanjing Well Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 603351 market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥3.00 Million	0.12%
Total Liquid Assets	CN¥3.00 Million	0.12%

Asset Resilience Insights

Limited Liquidity: Nanjing Well Pharmaceutical Co Ltd maintains only 0.12% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Nanjing Well Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Nanjing Well Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Zhejiang Huahai Pharmaceutical Co Ltd SHG:600521	Drug Manufacturers - Specialty & Generic	0.44%
Emcure Pharmaceuticals Ltd NSE:EMCURE	Drug Manufacturers - Specialty & Generic	1.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	Drug Manufacturers - Specialty & Generic	6.62%
Ningbo Menovo Pharm Co Ltd SHG:603538	Drug Manufacturers - Specialty & Generic	2.69%
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Changzhou Qianhong Biopharma Co Ltd SHE:002550	Drug Manufacturers - Specialty & Generic	20.24%
Hunan Warrant Pharmaceutical Co. Ltd. A SHG:688799	Drug Manufacturers - Specialty & Generic	0.40%

Annual Asset Resilience Ratio for Nanjing Well Pharmaceutical Co Ltd (2019–2023)

The table below shows the annual Asset Resilience Ratio data for Nanjing Well Pharmaceutical Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	0.05%	CN¥1.25 Million ≈ $183.19K	CN¥2.28 Billion ≈ $333.48 Million	+0.00pp
2022-12-31	0.05%	CN¥1.11 Million ≈ $161.86K	CN¥2.14 Billion ≈ $312.88 Million	-1.37pp
2021-12-31	1.42%	CN¥26.24 Million ≈ $3.84 Million	CN¥1.84 Billion ≈ $269.46 Million	-10.60pp
2020-12-31	12.02%	CN¥196.71 Million ≈ $28.78 Million	CN¥1.64 Billion ≈ $239.46 Million	+5.83pp
2019-12-31	6.19%	CN¥90.31 Million ≈ $13.22 Million	CN¥1.46 Billion ≈ $213.39 Million	--

pp = percentage points

About Nanjing Well Pharmaceutical Co Ltd

SHG:603351 China Drug Manufacturers - Specialty & Generic

Market Cap

$546.61 Million

CN¥3.74 Billion CNY

Market Cap Rank

#12106 Global

#3731 in China

Share Price

CN¥27.58

Change (1 day)

+1.62%

52-Week Range

CN¥23.50 - CN¥32.52

All Time High

CN¥40.56